Making the Case for Investment in Rural Cancer Control: An Analysis of Rural Cancer Incidence, Mortality, and Funding Trends

Estimates of those living in rural counties vary from 46.2 to 59 million, or 14% to 19% of the U.S. Rural communities face disadvantages compared with urban areas, including higher poverty, lower educational attainment, and lack of access to health services. We aimed to demonstrate rural-urban dispa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer epidemiology, biomarkers & prevention Jg. 26; H. 7; S. 992
Hauptverfasser: Blake, Kelly D, Moss, Jennifer L, Gaysynsky, Anna, Srinivasan, Shobha, Croyle, Robert T
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States 01.07.2017
Schlagworte:
ISSN:1538-7755, 1538-7755
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract Estimates of those living in rural counties vary from 46.2 to 59 million, or 14% to 19% of the U.S. Rural communities face disadvantages compared with urban areas, including higher poverty, lower educational attainment, and lack of access to health services. We aimed to demonstrate rural-urban disparities in cancer and to examine NCI-funded cancer control grants focused on rural populations. Estimates of 5-year cancer incidence and mortality from 2009 to 2013 were generated for counties at each level of the rural-urban continuum and for metropolitan versus nonmetropolitan counties, for all cancers combined and several individual cancer types. We also examined the number and foci of rural cancer control grants funded by NCI from 2011 to 2016. Cancer incidence was 447 cases per 100,000 in metropolitan counties and 460 per 100,000 in nonmetropolitan counties ( < 0.001). Cancer mortality rates were 166 per 100,000 in metropolitan counties and 182 per 100,000 in nonmetropolitan counties ( < 0.001). Higher incidence and mortality in rural areas were observed for cervical, colorectal, kidney, lung, melanoma, and oropharyngeal cancers. There were 48 R- and 3 P-mechanism rural-focused grants funded from 2011 to 2016 (3% of 1,655). Further investment is needed to disentangle the effects of individual-level SES and area-level factors to understand observed effects of rurality on cancer. .
AbstractList Estimates of those living in rural counties vary from 46.2 to 59 million, or 14% to 19% of the U.S.Estimates of those living in rural counties vary from 46.2 to 59 million, or 14% to 19% of the U.S.Rural communities face disadvantages compared with urban areas, including higher poverty, lower educational attainment, and lack of access to health services. We aimed to demonstrate rural-urban disparities in cancer and to examine NCI-funded cancer control grants focused on rural populations. Estimates of 5-year cancer incidence and mortality from 2009 to 2013 were generated for counties at each level of the rural-urban continuum and for metropolitan versus nonmetropolitan counties, for all cancers combined and several individual cancer types. We also examined the number and foci of rural cancer control grants funded by NCI from 2011 to 2016. Cancer incidence was 447 cases per 100,000 in metropolitan counties and 460 per 100,000 in nonmetropolitan counties (P < 0.001). Cancer mortality rates were 166 per 100,000 in metropolitan counties and 182 per 100,000 in nonmetropolitan counties (P < 0.001). Higher incidence and mortality in rural areas were observed for cervical, colorectal, kidney, lung, melanoma, and oropharyngeal cancers. There were 48 R- and 3 P-mechanism rural-focused grants funded from 2011 to 2016 (3% of 1,655). Further investment is needed to disentangle the effects of individual-level SES and area-level factors to understand observed effects of rurality on cancer. Cancer Epidemiol Biomarkers Prev; 26(7); 992-7. ©2017 AACR.POPULATIONRural communities face disadvantages compared with urban areas, including higher poverty, lower educational attainment, and lack of access to health services. We aimed to demonstrate rural-urban disparities in cancer and to examine NCI-funded cancer control grants focused on rural populations. Estimates of 5-year cancer incidence and mortality from 2009 to 2013 were generated for counties at each level of the rural-urban continuum and for metropolitan versus nonmetropolitan counties, for all cancers combined and several individual cancer types. We also examined the number and foci of rural cancer control grants funded by NCI from 2011 to 2016. Cancer incidence was 447 cases per 100,000 in metropolitan counties and 460 per 100,000 in nonmetropolitan counties (P < 0.001). Cancer mortality rates were 166 per 100,000 in metropolitan counties and 182 per 100,000 in nonmetropolitan counties (P < 0.001). Higher incidence and mortality in rural areas were observed for cervical, colorectal, kidney, lung, melanoma, and oropharyngeal cancers. There were 48 R- and 3 P-mechanism rural-focused grants funded from 2011 to 2016 (3% of 1,655). Further investment is needed to disentangle the effects of individual-level SES and area-level factors to understand observed effects of rurality on cancer. Cancer Epidemiol Biomarkers Prev; 26(7); 992-7. ©2017 AACR.
Estimates of those living in rural counties vary from 46.2 to 59 million, or 14% to 19% of the U.S. Rural communities face disadvantages compared with urban areas, including higher poverty, lower educational attainment, and lack of access to health services. We aimed to demonstrate rural-urban disparities in cancer and to examine NCI-funded cancer control grants focused on rural populations. Estimates of 5-year cancer incidence and mortality from 2009 to 2013 were generated for counties at each level of the rural-urban continuum and for metropolitan versus nonmetropolitan counties, for all cancers combined and several individual cancer types. We also examined the number and foci of rural cancer control grants funded by NCI from 2011 to 2016. Cancer incidence was 447 cases per 100,000 in metropolitan counties and 460 per 100,000 in nonmetropolitan counties ( < 0.001). Cancer mortality rates were 166 per 100,000 in metropolitan counties and 182 per 100,000 in nonmetropolitan counties ( < 0.001). Higher incidence and mortality in rural areas were observed for cervical, colorectal, kidney, lung, melanoma, and oropharyngeal cancers. There were 48 R- and 3 P-mechanism rural-focused grants funded from 2011 to 2016 (3% of 1,655). Further investment is needed to disentangle the effects of individual-level SES and area-level factors to understand observed effects of rurality on cancer. .
Author Blake, Kelly D
Croyle, Robert T
Moss, Jennifer L
Srinivasan, Shobha
Gaysynsky, Anna
Author_xml – sequence: 1
  givenname: Kelly D
  surname: Blake
  fullname: Blake, Kelly D
  email: kelly.blake@nih.gov
  organization: Division of Cancer Control and Population Sciences, NCI, NIH, Bethesda, Maryland. kelly.blake@nih.gov
– sequence: 2
  givenname: Jennifer L
  surname: Moss
  fullname: Moss, Jennifer L
  organization: Division of Cancer Control and Population Sciences, NCI, NIH, Bethesda, Maryland
– sequence: 3
  givenname: Anna
  surname: Gaysynsky
  fullname: Gaysynsky, Anna
  organization: Division of Cancer Control and Population Sciences, NCI, NIH, Bethesda, Maryland
– sequence: 4
  givenname: Shobha
  surname: Srinivasan
  fullname: Srinivasan, Shobha
  organization: Division of Cancer Control and Population Sciences, NCI, NIH, Bethesda, Maryland
– sequence: 5
  givenname: Robert T
  surname: Croyle
  fullname: Croyle, Robert T
  organization: Division of Cancer Control and Population Sciences, NCI, NIH, Bethesda, Maryland
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28600296$$D View this record in MEDLINE/PubMed
BookMark eNpVkF9LwzAUxYNMnJt-BCWPPqwzSZs08W2UTQsbisznkuWPVrtkJq0w8MNbcYLChXvg_jj3njsCA-edAeACoynGlF9jRGkiBKPT-UOZ4DxBSJAjcIppypM8p3TwRw_BKMZXhFAuKD0BQ8IZQkSwU_C5km-1e4bti4GFjAZaH2DpPkxst8a1sHbwsQuy6YdOmQAL79rgmxs4c33JZh_rCL39D5VO1dr0cgJXPrSyqdv9BEqn4aJz-nvdOhin4xk4trKJ5vzQx-BpMV8Xd8ny_rYsZstEZaloE221YplA3OSYsP5uxZmhVjElxGZDZcqwTAmlmeGC2T4b1SyV1hLCcCqwIGNw9eO7C_6966NV2zoq0zTSGd_FCvfeGeFU8B69PKDdZmt0tQv1VoZ99fsx8gXGBm97
CitedBy_id crossref_primary_10_3389_fcvm_2022_927769
crossref_primary_10_1089_thy_2023_0357
crossref_primary_10_1002_hed_26783
crossref_primary_10_1093_jnci_djab096
crossref_primary_10_1007_s00520_022_07544_y
crossref_primary_10_1016_j_whi_2017_09_008
crossref_primary_10_1111_jrh_12606
crossref_primary_10_3389_fonc_2023_1204821
crossref_primary_10_1097_NCC_0000000000000802
crossref_primary_10_1016_j_currproblcancer_2022_100893
crossref_primary_10_2217_mmt_2020_0023
crossref_primary_10_1111_jrh_12721
crossref_primary_10_1016_j_jaad_2021_03_086
crossref_primary_10_1053_j_gastro_2020_11_016
crossref_primary_10_1186_s12885_024_13040_9
crossref_primary_10_1016_j_ijrobp_2019_05_025
crossref_primary_10_1016_j_chest_2020_04_042
crossref_primary_10_1002_jgc4_1262
crossref_primary_10_1177_0272684X211065318
crossref_primary_10_1111_jrh_12615
crossref_primary_10_1200_GO_25_00018
crossref_primary_10_1097_MLR_0000000000002014
crossref_primary_10_1016_j_ijrobp_2022_06_075
crossref_primary_10_1111_jrh_12619
crossref_primary_10_1016_j_pec_2020_02_034
crossref_primary_10_1038_s41698_024_00547_4
crossref_primary_10_1007_s10147_022_02206_9
crossref_primary_10_2196_50392
crossref_primary_10_1002_pon_5596
crossref_primary_10_1097_MD_0000000000034692
crossref_primary_10_1111_jrh_12295
crossref_primary_10_1017_cts_2023_16
crossref_primary_10_3390_cancers17122051
crossref_primary_10_1016_j_ypmed_2019_105812
crossref_primary_10_1186_s12913_024_10916_1
crossref_primary_10_1186_s43058_020_00064_y
crossref_primary_10_1007_s00520_020_05342_y
crossref_primary_10_1001_jamanetworkopen_2023_50504
crossref_primary_10_1016_j_ygyno_2024_01_008
crossref_primary_10_1093_jncics_pkac017
crossref_primary_10_1016_j_jacr_2021_12_003
crossref_primary_10_1186_s43058_022_00311_4
crossref_primary_10_3390_ijerph19041916
crossref_primary_10_1007_s10552_021_01546_7
crossref_primary_10_1007_s00520_020_05497_8
crossref_primary_10_1016_j_cct_2021_106654
crossref_primary_10_1200_EDBK_238965
crossref_primary_10_1245_s10434_022_11834_4
crossref_primary_10_1097_MLR_0000000000001028
crossref_primary_10_1016_j_ypmed_2019_105821
crossref_primary_10_5888_pcd18_210091
crossref_primary_10_1007_s10552_023_01673_3
crossref_primary_10_1007_s13187_021_02069_0
crossref_primary_10_1186_s43058_022_00285_3
crossref_primary_10_1177_21501319241288025
crossref_primary_10_3390_app14125332
crossref_primary_10_1177_08901171241257051
crossref_primary_10_1002_cam4_70187
crossref_primary_10_1007_s11606_022_07922_6
crossref_primary_10_1007_s13187_020_01908_w
crossref_primary_10_1513_AnnalsATS_202103_333OC
crossref_primary_10_1002_cncr_32607
crossref_primary_10_1002_lary_30809
crossref_primary_10_1111_jrh_12881
crossref_primary_10_1111_jrh_12520
crossref_primary_10_1093_jnci_djac030
crossref_primary_10_1111_ijd_16459
crossref_primary_10_1038_s41598_022_18374_7
crossref_primary_10_1111_hex_13840
crossref_primary_10_1007_s11912_023_01415_3
crossref_primary_10_1002_cncr_33810
crossref_primary_10_1016_j_cct_2025_108005
crossref_primary_10_1186_s12913_023_09994_4
crossref_primary_10_1111_jrh_12414
crossref_primary_10_1002_cncr_33256
crossref_primary_10_1016_j_ypmed_2020_106407
crossref_primary_10_1016_j_cct_2024_107539
crossref_primary_10_1097_MLR_0000000000001691
crossref_primary_10_1007_s00520_025_09208_z
crossref_primary_10_1002_cam4_4944
crossref_primary_10_1007_s10552_023_01743_6
crossref_primary_10_3390_ijerph18041384
crossref_primary_10_1177_21501319241259915
crossref_primary_10_1186_s12885_021_08949_4
crossref_primary_10_15580_gjeph_2025_1_081125118
crossref_primary_10_1016_j_jaad_2020_08_092
crossref_primary_10_1016_j_conctc_2024_101399
crossref_primary_10_1111_jrh_12781
crossref_primary_10_1111_jrh_12420
crossref_primary_10_1111_jrh_12663
crossref_primary_10_1007_s13187_025_02708_w
crossref_primary_10_1002_pon_5566
crossref_primary_10_1002_cncr_32398
crossref_primary_10_1200_GO_23_00238
crossref_primary_10_2196_66636
crossref_primary_10_1186_s12889_025_22134_3
crossref_primary_10_3390_ijerph19116874
crossref_primary_10_1093_jnci_djac038
crossref_primary_10_1111_jrh_12550
crossref_primary_10_1007_s10552_024_01851_x
crossref_primary_10_1007_s10552_022_01599_2
crossref_primary_10_4251_wjgo_v16_i4_1374
crossref_primary_10_1093_jnci_djab139
crossref_primary_10_3389_fonc_2024_1373905
crossref_primary_10_1186_s40959_023_00167_0
crossref_primary_10_1097_JHQ_0000000000000354
crossref_primary_10_1002_cnr2_1354
crossref_primary_10_1007_s00520_020_05674_9
crossref_primary_10_1111_jpc_16469
crossref_primary_10_1016_j_canep_2023_102512
crossref_primary_10_1186_s12913_024_12014_8
crossref_primary_10_1002_cncr_32651
crossref_primary_10_1007_s11764_024_01546_x
crossref_primary_10_1093_jnci_djab006
crossref_primary_10_5888_pcd19_210450
crossref_primary_10_1016_j_amepre_2021_05_021
crossref_primary_10_1016_j_jss_2022_10_097
crossref_primary_10_1016_j_jgo_2020_09_003
crossref_primary_10_1007_s10549_022_06830_x
crossref_primary_10_1007_s10900_021_01035_7
crossref_primary_10_1177_1178223419876296
crossref_primary_10_1177_12034754241247521
crossref_primary_10_1002_cnr2_1221
crossref_primary_10_3390_ijerph16030436
crossref_primary_10_1089_jayao_2019_0102
crossref_primary_10_1177_12034754221149653
crossref_primary_10_1188_19_ONF_654_669
crossref_primary_10_3389_fmed_2025_1427136
crossref_primary_10_1111_jrh_12455
crossref_primary_10_1111_jrh_12335
crossref_primary_10_1016_j_puhe_2020_09_018
crossref_primary_10_1089_jwh_2021_0517
crossref_primary_10_1016_j_jcpo_2023_100465
crossref_primary_10_1177_10732748221102819
crossref_primary_10_1111_jrh_12571
crossref_primary_10_1016_j_urolonc_2019_03_004
crossref_primary_10_1016_j_ssmqr_2024_100519
crossref_primary_10_5888_pcd19_220104
crossref_primary_10_1089_heq_2021_0068
crossref_primary_10_1249_TJX_0000000000000288
crossref_primary_10_1177_23743735241239865
crossref_primary_10_1002_cam4_7058
crossref_primary_10_1188_21_CJON_S1_10_16
crossref_primary_10_1007_s10552_024_01867_3
crossref_primary_10_1016_j_jth_2019_100625
crossref_primary_10_1002_cncr_31541
crossref_primary_10_1017_cts_2025_10123
crossref_primary_10_1016_j_imr_2021_100755
crossref_primary_10_1371_journal_pone_0331685
crossref_primary_10_1016_j_ijrobp_2023_10_030
crossref_primary_10_1093_jnci_djac238
crossref_primary_10_1111_add_16355
crossref_primary_10_1007_s11136_020_02683_3
crossref_primary_10_1016_j_jss_2019_03_008
crossref_primary_10_1016_j_ypmed_2023_107588
crossref_primary_10_1002_ajim_23524
crossref_primary_10_3390_ijerph182412909
crossref_primary_10_1007_s10552_020_01375_0
crossref_primary_10_1016_j_jtho_2017_12_010
crossref_primary_10_1093_jncics_pkaa100
crossref_primary_10_1186_s12885_021_08985_0
crossref_primary_10_1111_jrh_12357
crossref_primary_10_1177_23333936221111802
crossref_primary_10_1016_j_jacr_2022_12_019
crossref_primary_10_1186_s12911_021_01549_z
crossref_primary_10_1111_jrh_12359
crossref_primary_10_1007_s11912_024_01534_5
crossref_primary_10_1016_j_jss_2021_09_042
crossref_primary_10_1111_jrh_12590
crossref_primary_10_1111_jrh_12350
crossref_primary_10_1007_s00520_019_05005_7
crossref_primary_10_1007_s40615_025_02517_3
crossref_primary_10_1016_j_jaad_2024_01_042
crossref_primary_10_1016_j_ypmed_2019_105835
crossref_primary_10_1245_s10434_021_11304_3
crossref_primary_10_1016_j_cct_2023_107276
crossref_primary_10_1093_eurheartj_ehae047
crossref_primary_10_1186_s12913_021_06489_y
crossref_primary_10_1016_j_canep_2021_102033
crossref_primary_10_1111_jrh_12364
crossref_primary_10_1016_j_suronc_2024_102034
crossref_primary_10_1016_j_suc_2024_11_008
crossref_primary_10_1186_s12913_022_08976_2
crossref_primary_10_1016_j_worlddev_2022_105941
crossref_primary_10_1016_j_ypmed_2019_105849
crossref_primary_10_1093_jncimonographs_lgae003
crossref_primary_10_1016_j_jgo_2021_04_002
crossref_primary_10_1002_cam4_6830
crossref_primary_10_1007_s00520_019_05134_z
crossref_primary_10_1111_jrh_12498
crossref_primary_10_1016_j_jacr_2023_01_003
crossref_primary_10_1080_13557858_2022_2056145
crossref_primary_10_1093_tbm_ibz035
crossref_primary_10_1016_j_amjsurg_2023_09_029
crossref_primary_10_1016_j_jth_2024_101819
crossref_primary_10_1016_j_jaad_2020_07_125
crossref_primary_10_3390_ijerph192315887
crossref_primary_10_1007_s13187_020_01696_3
crossref_primary_10_1007_s13187_020_01819_w
crossref_primary_10_1016_j_canep_2020_101681
crossref_primary_10_1111_jrh_12821
crossref_primary_10_1007_s00520_024_08457_8
crossref_primary_10_1016_j_ypmed_2021_106759
crossref_primary_10_1245_s10434_025_17291_z
crossref_primary_10_1007_s10865_023_00400_2
crossref_primary_10_1016_j_ygyno_2021_07_035
crossref_primary_10_1111_jrh_12263
crossref_primary_10_1016_j_urolonc_2023_12_011
crossref_primary_10_1016_j_amepre_2020_03_019
crossref_primary_10_1200_EDBK_390678
crossref_primary_10_1007_s13187_024_02550_6
crossref_primary_10_3390_nu15183998
crossref_primary_10_1016_j_japh_2023_09_004
crossref_primary_10_1001_jamanetworkopen_2022_12246
crossref_primary_10_1016_j_amepre_2021_09_021
crossref_primary_10_3389_fonc_2024_1374403
crossref_primary_10_1007_s10552_022_01621_7
crossref_primary_10_1002_pon_5616
crossref_primary_10_1089_whr_2021_0082
crossref_primary_10_1097_PPO_0000000000000686
crossref_primary_10_1111_jrh_12399
crossref_primary_10_1136_jech_2019_212425
crossref_primary_10_14423_SMJ_0000000000001171
crossref_primary_10_1186_s12913_025_12988_z
crossref_primary_10_1016_j_jcpo_2020_100262
crossref_primary_10_1007_s10552_023_01819_3
crossref_primary_10_1186_s12875_022_01845_1
crossref_primary_10_11124_JBIES_21_00256
crossref_primary_10_1016_j_canep_2024_102705
ContentType Journal Article
Copyright 2017 American Association for Cancer Research.
Copyright_xml – notice: 2017 American Association for Cancer Research.
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1158/1055-9965.EPI-17-0092
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 1538-7755
ExternalDocumentID 28600296
Genre Journal Article
GrantInformation_xml – fundername: Intramural NIH HHS
  grantid: Z99 CA999999
GroupedDBID ---
.55
18M
29B
2FS
2WC
34G
39C
3O-
53G
5GY
5VS
6J9
AAFWJ
ABOCM
ACPRK
ADBBV
ADCOW
AENEX
AFHIN
AFRAH
AI.
ALMA_UNASSIGNED_HOLDINGS
BR6
BTFSW
C1A
CGR
CS3
CUY
CVF
DIK
DU5
E3Z
EBS
ECM
EIF
EJD
F5P
FRP
H13
H~9
IH2
KQ8
L7B
NPM
OK1
P2P
PQQKQ
QTD
RCR
RHI
SJN
UDS
VH1
W8F
WHG
WOQ
X7M
ZXP
7X8
ID FETCH-LOGICAL-c439t-dfdc64908e7126029c86e5fc6c99bb5a361a32554e896f2865d63aff226139192
IEDL.DBID 7X8
ISICitedReferencesCount 303
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000415229200002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1538-7755
IngestDate Fri Jul 11 12:18:29 EDT 2025
Mon Jul 21 05:50:34 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 7
Language English
License 2017 American Association for Cancer Research.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c439t-dfdc64908e7126029c86e5fc6c99bb5a361a32554e896f2865d63aff226139192
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/5500425
PMID 28600296
PQID 1908428598
PQPubID 23479
ParticipantIDs proquest_miscellaneous_1908428598
pubmed_primary_28600296
PublicationCentury 2000
PublicationDate 2017-07-01
PublicationDateYYYYMMDD 2017-07-01
PublicationDate_xml – month: 07
  year: 2017
  text: 2017-07-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Cancer epidemiology, biomarkers & prevention
PublicationTitleAlternate Cancer Epidemiol Biomarkers Prev
PublicationYear 2017
SSID ssj0007955
Score 2.640113
SecondaryResourceType review_article
Snippet Estimates of those living in rural counties vary from 46.2 to 59 million, or 14% to 19% of the U.S. Rural communities face disadvantages compared with urban...
Estimates of those living in rural counties vary from 46.2 to 59 million, or 14% to 19% of the U.S.Estimates of those living in rural counties vary from 46.2...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 992
SubjectTerms Financing, Government - standards
Financing, Government - trends
Healthcare Disparities - statistics & numerical data
Healthcare Disparities - trends
Humans
Incidence
National Cancer Institute (U.S.) - economics
National Cancer Institute (U.S.) - statistics & numerical data
National Cancer Institute (U.S.) - trends
Neoplasms - epidemiology
Neoplasms - therapy
Rural Health - standards
Rural Health - trends
Rural Health Services - economics
Rural Health Services - organization & administration
Rural Health Services - statistics & numerical data
Rural Health Services - trends
Rural Population - statistics & numerical data
SEER Program - statistics & numerical data
United States
Urban Health
Urban Health Services - economics
Urban Health Services - organization & administration
Urban Health Services - statistics & numerical data
Urban Health Services - trends
Urban Population - statistics & numerical data
Title Making the Case for Investment in Rural Cancer Control: An Analysis of Rural Cancer Incidence, Mortality, and Funding Trends
URI https://www.ncbi.nlm.nih.gov/pubmed/28600296
https://www.proquest.com/docview/1908428598
Volume 26
WOSCitedRecordID wos000415229200002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bS8MwFA7qRHzxfpk3Ivi4OLq0ufgiMjYU7BiisreS5gJ7aecuPvnjPUk7hg-C4Ev60JaW5OScLzkn34fQDXeRYC4XJOfakjhyCuaciIhRDOyHMsoDA9_7Mx8MxGgkh_WG26wuq1z6xOCoTan9HnkbApeIPduauJ98EK8a5bOrtYTGOmpQgDLeqvloxRbOZVA9DZOa8ySpT_BEiWh7XUgCWD-57Q2fCHhqTz70O8oM0aa_-9__3EM7Nc7ED5Vh7KM1WxygrbTOpB-irzTIUGHAf7gLkQwDeMUV6YbfL8TjAr94Rg64CWYxxd2qpP0OPxR4SWSCS_fzIXA2lUZpC6cB1gPEb2FVGNxfhNMzuCrBPUJv_d5r95HUSgxEA2CZE-OMZj5FaHkEC6CO1ILZxGmmpczzRFEWKQqLk9gKyZw_7GoYVc4BtoNhARB5jDaKsrCnCFNupI21gVbEcFU8YdZy5qiEeGpFE10v-zUDS_fpC1XYcjHLVj3bRCfV4GSTipIjg0_6_CI7-8Pb52i742NzqLm9QA0H89xeok39OR_PplfBhKAdDNNvGDTOuA
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Making+the+Case+for+Investment+in+Rural+Cancer+Control%3A+An+Analysis+of+Rural+Cancer+Incidence%2C+Mortality%2C+and+Funding+Trends&rft.jtitle=Cancer+epidemiology%2C+biomarkers+%26+prevention&rft.au=Blake%2C+Kelly+D&rft.au=Moss%2C+Jennifer+L&rft.au=Gaysynsky%2C+Anna&rft.au=Srinivasan%2C+Shobha&rft.date=2017-07-01&rft.eissn=1538-7755&rft.volume=26&rft.issue=7&rft.spage=992&rft_id=info:doi/10.1158%2F1055-9965.EPI-17-0092&rft_id=info%3Apmid%2F28600296&rft_id=info%3Apmid%2F28600296&rft.externalDocID=28600296
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1538-7755&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1538-7755&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1538-7755&client=summon